FrancophonIA/ELRC3.0 huggingface dataset:
English: There are no safety data from bedaquiline multiple dose trials which utilised a dose higher than the indicated dose.
Slovenian: Iz študij z večkratnim odmerjanjem bedakilina, v katerih so uporabljali odmerke, ki so bili večji od indiciranega, ni na voljo podatkov o varnosti zdravila.
English: In an interaction study of single-dose bedaquiline and multiple-dose lopinavir/ritonavir, exposure (AUC) to bedaquiline was increased by 22% [90% CI (11; 34)].
Slovenian: V študiji medsebojnega delovanja, v kateri so preiskovanci prejeli enkraten odmerek bedakilina in več odmerkov lopinavirja oziroma ritonavirja, se je izpostavljenost bedakilinu (AUC) povečala za 22% [90-odstotni IZ (11; 34)].
English: Pre-extensively drug resistant tuberculosis (pre-XDR-TB): isolate resistant to isoniazid, rifampicin, and either any fluoroquinolone or at least one second line injectable agent (but not to both a fluoroquinolone and a second line injectable agent).
Slovenian: Predstopnja izredno odpornih sevov tuberkuloze (pre-XDR-TB): izolat, odporen na izoniazid, rifampicin in ali na katerikoli fluorokinolon ali vsaj na eno učinkovino drugega reda za injiciranje (ne pa na oboje: fluorokinolon in učinkovino drugega reda za injiciranje).
English: Conversion rates at week 120 were highest (73.1%; 68/93) in patients with MDRH&R-TB, 70.5% (31/44) in pre-XDR-TB patients and lowest (62.2%; 23/37) in XDR-TB patients.
Slovenian: V 120. tednu zdravljenja je bila pogostnost konverzij največja pri bolnikih z MDRH&R-TB (73,1%; 68/93), 70,5% (31/44) pri bolnikih s pre-XDR-TB, najmanjša (62,2%; 23/37) pa je bila pri bolnikih z XDR-TB.
English: Extensively drug resistant tuberculosis (XDR-TB): isolate resistant to isoniazid, rifampicin, any fluoroquinolone, and at least one second line injectable agent.
Slovenian: Proti zdravilom izredno odporna tuberkuloza (XDR-TB): izolat, odporen na izoniazid, rifampicin, katerikoli fluorokinolon in vsaj eno učinkovino drugega reda za injiciranje.
English: Body weight decreases in pups were noted in high dose groups during the lactation period after exposure to bedaquiline via milk and were not a consequence of in utero exposure.
Slovenian: V skupinah podgan, ki so jim dajali visoke odmerke bedakilina v času dojenja, so opažali zmanjšanje telesne mase mladičev, do katerega je prišlo zaradi izpostavljenosti bedakilinu iz materinega mleka in ne zaradi izpostavljenosti plodu v maternici.
English: Patients with MDRH&R-TB Patients infected with pre-XDR-TB Overall non-responder* at Week 120
Slovenian: MDRH&R-TB bolniki s pre-XDR-TB skupno število bolnikov brez odziva* po 120 tednih brez konverzije ponovitev bolezni konverzija kljub prekinitvi zdravljenja
English: Commonly susceptible species Mycobacterium tuberculosis
Slovenian: Organizmi, ki so pogosto občutljivi na učinkovino Mycobacterium tuberculosis
English: SIRTURO contains the active substance bedaquiline.
Slovenian: Zdravilo SIRTURO vsebuje zdravilno učinkovino bedakilin.
English: Medicinal product subject to restricted medical prescription (see Annex I: Summary of Product Characteristics, section 4.2).
Slovenian: (Glejte Prilogo I: Povzetek glavnih značilnosti zdravila, poglavje 4.2).
English: How much to take You take SIRTURO for a 24 week course.
Slovenian: Koliko zdravila jemati Zdravilo SIRTURO je treba jemati 24 tednov.
English: No dose adjustment is required in patients with mild or moderate renal impairment.
Slovenian: Pri bolnikih z blago ali zmerno okvaro ledvic prilagajanje odmerjanja ni potrebno.
English: Interactions with other medicinal products
Slovenian: Medsebojno delovanje z drugimi zdravili:
English: Extent of resistance based on central laboratory drug susceptibility testing results was not available for 20 subjects in the mITT population (12 in the SIRTURO group and 8 in the placebo group).
Slovenian: Za 20 preiskovancev v mITT populaciji (12 v skupini, ki je prejemala zdravilo SIRTURO, in 8 v skupini, ki je prejemala placebo) obseg odpornosti na osnovi rezultatov testiranja občutljivosti v centralnem laboratoriju ni bil na voljo.
English: Bedaquiline must only be used in an appropriate combination regimen for MDR-TB treatment as recommended by official guidelines, such as from WHO, to prevent development of resistance to bedaquiline.
Slovenian: Za preprečevanje razvoja rezistence na bedakilin je treba bedakilin uporabljati samo v okviru ustreznih kombiniranih shem zdravljenje tuberkuloze, odporne proti več zdravilom, torej v okviru shem, ki so priporočene v uradnih smernicah, kot so smernice SZO.
English: Patients receiving SIRTURO alone with no other QT prolonging medicinal product developed a maximal mean QTcF increase over baseline of 23.7 ms with no QT duration in excess of 480 ms, whereas patients with at least 2 other QT prolonging medicinal products developed a maximal mean QTcF prolongation of 30.7 ms over baseline, resulting in a QTcF duration in excess of 500 ms in one patient.
Slovenian: Pri bolnikih, ki ob prejemanju zdravila SIRTURO niso prejemali drugih učinkovin, ki podaljšujejo interval QT, je bilo največje povprečno povečanje intervala QTcF 23,7 ms glede na izhodiščno vrednost, pri čemer nobeno trajanje intervala QT ni presegalo 480 ms.
English: Body weight decreases in pups were noted in high dose groups during the lactation period (see section 5.3).
Slovenian: V skupini podgan, ki so v času dojenja prejemale visoke odmerke zdravila, so opažali zmanjšanje telesne mase mladičev (glejte poglavje 5.3).
English: As bedaquiline is highly bound to plasma proteins, it is unlikely that it will be significantly removed from plasma by haemodialysis or peritoneal dialysis.
Slovenian: Bedakilin se obsežno veže na beljakovine v plazmi, zato ga s hemodializo ali peritonealno dializo predvidoma ni mogoče v večji meri odstraniti iz plazme.
English: Since bedaquiline is highly protein-bound, dialysis is not likely to significantly remove bedaquiline from plasma.
Slovenian: Bedakilin se obsežno veže na beljakovine, zato ga z dializo predvidoma ni mogoče v večji meri odstraniti iz plazme.
English: Treatment with the other agents in the regimen should continue after completion of treatment with SIRTURO.
Slovenian: Po zaključku zdravljenja z zdravilom SIRTURO je treba nadaljevati zdravljenje z drugimi učinkovinami, ki so del sheme.
English: SIRTURO should be used with caution in patients with moderate hepatic impairment (see section 5.2).
Slovenian: Pri bolnikih z zmerno jetrno okvaro je treba zdravilo SIRTURO uporabljati previdno (glejte poglavje 5.2).
English: If co-administration is required, more frequent electrocardiogram monitoring and monitoring of transaminases is recommended (see section 4.4).
Slovenian: Če je sočasna uporaba kljub vsemu potrebna, je priporočeno pogostejše spremljanje električne aktivnosti srca (elektrokardiogram) in koncentracij aminotransferaz (glejte poglavje 4.4).
English: • Heart failure;
Slovenian: • s srčnim popuščanjem
English: • you have a decreased thyroid gland function.
Slovenian: • če imate zmanjšano delovanje ščitnice.
English: Store SIRTURO in the original container or package in order to protect it from light.
Slovenian: Zdravilo SIRTURO shranjujte v originalni ovojnini za zagotovitev zaščite pred svetlobo
English: See section 4.5, QT interval and concomitant clofazimine use, for further information regarding patients using clofazimine concomitantly.
Slovenian: Za dodatne podatke o bolnikih, ki sočasno jemljejo klofazimin glejte poglavje 4.5 Interval QT in sočasna uporaba klofazimina.
English: When bedaquiline is co-administered with other medicinal products that prolong the QTc interval (including delamanid and levofloxacin), an additive or synergistic effect on QT prolongation cannot be excluded (see section 4.5).
Slovenian: Pri sočasni uporabi bedakilina z drugimi zdravili, ki podaljšajo interval QTc (vključno z delamanidom in levofloksacinom), ni mogoče izključiti dodatnega ali sinergističnega učinka na podaljšanje intervala QT (glejte poglavje 4.5) Pri predpisovanju bedakilina sočasno z zdravili z znanim tveganjem za podaljšanje intervala QT je potrebna previdnost.
English: Microcrystalline cellulose Croscarmellose sodium Silica, colloidal anhydrous Magnesium stearate
Slovenian: 6.1 Seznam pomožnih snovi laktoza monohidrat koruzni škrob hipromeloza polisorbat 20 mikrokristalna celuloza premrežen natrijev karmelozat brezvodni koloidni silicijev dioksid magnezijev stearat
English: SIRTURO contains lactose.
Slovenian: Zdravilo SIRTURO vsebuje laktozo.
English: Driving and using machines You may feel dizzy after taking SIRTURO.
Slovenian: Vpliv na sposobnost upravljanja vozil in strojev Po jemanju zdravila SIRTURO lahko postanete omotični.
English: System Organ Class (SOC) Frequency Category
Slovenian: Kategorija pogostnosti
English: Pharmacokinetic/pharmacodynamic relationship
Slovenian: Razmerje med farmakokinetičnimi in farmakodinamičnimi lastnostmi zdravila
English: In patients with severe renal impairment (creatinine clearance < 30 ml/min) or end-stage renal disease requiring haemodialysis or peritoneal dialysis, SIRTURO should be used with caution (see section 5.2).
Slovenian: Previdnost je potrebna pri uporabi zdravila SIRTURO pri bolnikih s hudo okvaro ledvic (očistek kreatinina < 30 ml/min) ali s končno ledvično odpovedjo, zaradi katere je potrebno zdravljenje s hemodializo ali peritonealno dializo (glejte poglavje 5.2).
English: QT prolongation (i.e., gatifloxacin, moxifloxacin and sparfloxacin).
Slovenian: • ki sočasno jemljejo fluorokinolonske antibiotike, ki lahko pomembno podaljšajo interval QT (to so gatifloksacin, moksifloksacin in sparfloksacin)
English: A more pronounced effect on bedaquiline may be observed during prolonged co-administration of ketoconazole or other inhibitors of CYP3A4.
Slovenian: Pri dolgotrajni sočasni uporabi ketokonazola ali drugih zaviralcev encima CYP3A4 je mogoče opaziti izrazitejši učinek na bedakilin.
English: Extent of resistance based on central laboratory drug susceptibility testing results was not available for 32 subjects in the mITT population.
Slovenian: Pri 32 preskušancih v mITT populaciji ni bilo podatkov o obsegu odpornosti (na osnovi rezultatov testiranja občutljivosti centralnega laboratorija).
English: • A history of Torsade de Pointes;
Slovenian: • ki so v preteklosti imeli torsade de pointes (vrsto polimorfne ventrikularne tahikardije)
English: • A history of or ongoing hypothyroidism;
Slovenian: • s hipotiroidizmom ali bolnikih, ki so v preteklosti imeli hipotiroidizem
English: No dose adjustment is necessary for SIRTURO in patients with mild or moderate hepatic impairment (see section 5.2).
Slovenian: Pri bolnikih z blago ali zmerno okvaro jeter prilagajanje odmerjanja zdravila SIRTURO ni potrebno (glejte poglavje 5.2).
English: 133-fold increases in bedaquiline MIC, resulting in MICs ranging from 0.25 to 4 mg/l.
Slovenian: Tarčne mutacije, razvite v predkliničnih študijah so vodile v 8 do 133-kratno zvečanje MIK bedakilina in so dosegle koncentracije 0,25 do 4 mg/l.
English: There is limited clinical data (n = 2) on the use of SIRTURO in tuberculosis patients aged 65 years and older.
Slovenian: Kliničnih podatkov o uporabi zdravila SIRTURO pri bolnikih s tuberkulozo, ki so stari 65 let ali več, je zelo malo (n = 2).
English: Increased transaminases
Slovenian: Zvišanje koncentracije aminotransferaz
English: What SIRTURO contains
Slovenian: Kaj vsebuje zdravilo SIRTURO
English: One death in the SIRTURO group and one death in the placebo group were reported after the week 120 window.
Slovenian: Po koncu 120-tedenskega obdobja zdravljenja so poročali o enem smrtnem primeru v skupini z zdravilom SIRTURO in o enem smrtnem primeru v skupini s placebom.
English: • A history of or ongoing bradyarrhythmia;
Slovenian: • z bradiaritmijo ali bolnikih, ki so v preteklosti imeli bradiaritmijo
English: Increases in transaminases or aminotransferase elevations accompanied by total bilirubin ≥ 2x ULN were seen in clinical trials during administration of SIRTURO with the background regimen (see section 4.8).
Slovenian: V kliničnih študijah so v času uporabe zdravila SIRTURO skupaj z osnovno shemo zdravljenja opažali zvišanja koncentracije aminotransferaz ali zvišanja koncentracije aminotransferaze, s spremljajočim skupnim bilirubinom ≥ 2x ULN (glejte poglavje 4.8).
English: Cases of intentional or accidental acute overdose with bedaquiline were not reported during clinical trials.
Slovenian: Med izvajanjem kliničnih študij niso poročali o nobenem primeru namernega ali nenamernega akutnega prevelikega odmerjanja bedakilina.
English: No relevant bedaquiline-related effects on developmental toxicity parameters were observed in rats and rabbits.
Slovenian: Pri podganah in kuncih niso opažali nobenih pomembnih učinkov bedakilina na parametre za oceno razvojne toksičnosti.
English: Cardiac disorders
Slovenian: Kardiovaskularni neželeni učinki
English: Do not take SIRTURO if this applies to you.
Slovenian: Če to velja za vas, ne jemljite zdravila SIRTURO.
English: Increases in plasma exposure to bedaquiline would be expected when it is coadministered with other ritonavir-boosted HIV protease inhibitors.
Slovenian: Pri sočasni uporabi z drugimi z ritonavirjem okrepljenimi zaviralci HIV proteaze je pričakovati zvečanje plazemske izpostavljenosti bedakilinu.
English: Refer to the Summary of Product Characteristics of the medicinal products used in combination with SIRTURO for their specific dosing recommendations.
Slovenian: Za priporočila glede odmerjanja zdravil, ki se uporabljajo v kombinaciji z zdravilom SIRTURO glejte povzetke glavnih značilnosti teh zdravil.
English: If co-administration is required, more frequent electrocardiogram monitoring and monitoring of transaminases is recommended.
Slovenian: Če je sočasna uporaba kljub vsemu potrebna, je priporočeno pogostejše spremljanje električne aktivnosti bolnikovega srca (elektrokardiogram) in koncentracij aminotransferaz.
English: No structural abnormalities in the testes and epididymides were seen after up to 6-months of bedaquiline treatment.
Slovenian: Po največ 6-mesečnem dajanju bedakilina niso opažali nobenih strukturnih nepravilnosti v modih in epididimisu.
English: Bedaquiline is bacteriostatic for many non-tuberculous mycobacterial species.
Slovenian: Na številne netuberkulozne mikobakterije bedakilin deluje bakteriostatično.
English: Therefore, bedaquiline should be taken with food to enhance its oral bioavailability.
Slovenian: Za povečanje peroralne biološke uporabnosti bedakilina je treba torej zdravilo jemati skupaj s hrano.
English: Of note, no change in bedaquiline dosing is recommended in case of co-treatment with lopinavir/ritonavir or other ritonavir-boosted HIV protease inhibitors.
Slovenian: Pri sočasni uporabi bedakilina z lopinavirjem/ritonavirjem ali z drugimi z ritonavirjem okrepljenimi zaviralci HIV proteaze spremembe v odmerjanju badakilina niso priporočljive.
English: 0.25 mg/l
Slovenian: 0,25 mg/l klinična mejna vrednost
English: In the mouse model for TB infection, bedaquiline has demonstrated bactericidal and sterilizing activities.
Slovenian: Bedakilin deluje baktericidno tudi na mirujoče bacile tuberkuloze (ki niso v fazi razmnoževanja).Na mišjem modelu okužbe z bacilom tuberkuloze je bedakilin deloval baktericidno in sterilizacijsko.
English: Refer to the Summary of Product Characteristics of the medicinal products used in combination with SIRTURO for their respective adverse reactions.
Slovenian: Za neželene učinke zdravil, ki se uporabljajo v kombinaciji z zdravilom SIRTURO, glejte povzetke glavnih značilnosti teh zdravil.
English: How to store SIRTURO
Slovenian: Shranjevanje zdravila SIRTURO
English: A more pronounced effect on bedaquiline plasma exposures may be observed during prolonged co-administration with lopinavir/ritonavir.
Slovenian: Pri dolgotrajni sočasni uporabi z lopinavirjem oziroma ritonavirjem je mogoče opaziti izrazitejši učinek na plazemsko izpostavljenost bedakilinu.
English: Tell your doctor right away if you faint.
Slovenian: Če izgubite zavest, takoj obvestite zdravnika.
English: (antimycobacterial) carbamazepine, phenytoin to treat epileptic fits (anticonvulsants) St. John's wort (Hypericum perforatum)
Slovenian: karbamazepin, fenitoin za zdravljenje epileptičnih napadov (antiepileptiki)
English: Electrocardiogram QT prolonged
Slovenian: Srčne bolezni pogosti podaljšanje intervala QT na elektrokardiogramu
English: No dose-adjustment of isoniazid or pyrazinamide is required during co-administration with bedaquiline.
Slovenian: Pri sočasni uporabi z bedakilinom prilagajanje odmerjanja izoniazida oziroma pirazinamida ni potrebno.
English: Overall responder at Week 24 Patients with MDRH&R-TB Patients infected with a pre-XDR-TB Overall nonresponder* at Week 24
Slovenian: Populacija mITT n SIRTURO/osnovna shema n placebo/osnovna shema skupno število bolnikov z odzivom po 24 tednih bolniki z MDRH&R-TB bolniki s pre-XDR-TB
English: • Take 400 mg (4 tablets of 100 mg) once a day.
Slovenian: • jemljete 400 mg (4 tablete po 100 mg) enkrat na dan. Od začetka 3. do konca 24. tedna:
English: Myalgia * Terms represented by ‘transaminases increased' included AST increased, ALT increased, hepatic enzyme increased,
Slovenian: Bolezni mišično-skeletnega sistema in vezivnega tkiva zelo pogosti artralgija pogosti mialgija * Izraz "zvišanje koncentracije aminotransferaz" vključuje zvišanje koncentracije aspartat-aminotransferaze, alanin aminotransferaze, jetrnih encimov, nenormalno delovanje jeter in zvišanje koncentracije aminotransferaz (glejte poglavje spodaj).
English: • feeling dizzy
Slovenian: • občutek omotičnosti
English: No dose adjustment is deemed necessary in patients with mild or moderate hepatic impairment.
Slovenian: Pri bolnikih z blago ali zmerno okvaro jeter velja, da prilagajanje odmerjanja ni potrebno.
English: Talk to your doctor, pharmacist or nurse before taking SIRTURO, if:
Slovenian: Pred začetkom jemanja zdravila SIRTURO se posvetujte z zdravnikom, farmacevtom ali medicinsko sestro:
English: Bedaquiline exposure may be increased during co-administration with inhibitors of CYP3A4.
Slovenian: Pri sočasni uporabi z zaviralci encima CYP3A4 je izpostavljenost bedakilinu lahko povečana.
English: In patients with extensive drug resistance, where SIRTURO is considered necessary beyond 24 weeks to obtain a curative treatment, a longer duration of therapy may be considered only on a case by case basis and under close safety surveillance (see section 4.8).
Slovenian: O podaljšanju zdravljenja (na več kot 24 tednov) za doseganje ozdravitve se pri bolnikih z izredno odpornostjo na zdravila (XDR -extensive drug resistance) lahko odločate posamezno za vsak primer.
English: Bedaquiline exposure may be reduced during co-administration with inducers of CYP3A4.
Slovenian: Pri sočasni uporabi z induktorji encima CYP3A4 je izpostavljenost bedakilinu lahko zmanjšana.
English: Nervous system disorders
Slovenian: Organski sistem
English: The European Commission granted a marketing authorisation valid throughout the European Union for Cosentyx on 15 January 2015.
Slovenian: Evropska komisija je dovoljenje za promet z zdravilom Cosentyx, veljavno po vsej Evropski uniji, izdala 15. januarja 2015.
English: An improvement is usually seen within 16 weeks of treatment.
Slovenian: Do izboljšanja običajno pride po 16 tednih zdravljenja.
English: Cosentyx secukinumab
Slovenian: Cosentyx sekukinumab
English: The dose to be used depends on the disease to be treated.
Slovenian: Uporabljeni odmerek je odvisen od zdravljene bolezni.
English: Because Cosentyx may increase the risk of infection, it must not be given to patients with serious active infections such as tuberculosis.
Slovenian: Ker lahko zdravilo Cosentyx poveča tveganje za okužbo, se ne sme dajati bolnikom z resnimi aktivnimi okužbami, kot je tuberkuloza.
English: This is a summary of the European public assessment report (EPAR) for Cosentyx.
Slovenian: To je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Cosentyx.
English: The safety profile was considered reassuring, with the main concern related to mild infections.
Slovenian: Varnostni profil je bil ocenjen kot spodbuden, glavni pomislek pa je povezan z blagimi okužbami.
English: Some patients with an initial partial improvement may see further improvements with continued treatment beyond 16 weeks.
Slovenian: Pri nekaterih bolniki z delnim začetnim izboljšanjem se lahko z nadaljevanjem zdravljenja po 16 tednih stanje še dodatno izboljša.
English: The full EPAR and risk management plan summary for Cosentyx can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Slovenian: Celotno evropsko javno poročilo o oceni zdravila (EPAR) in povzetek načrta obvladovanja tveganj za zdravilo Cosentyx sta na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: The Agency's Committee for Medicinal Products for Human Use (CHMP) decided that Cosentyx's benefits are greater than its risks and recommended that it be approved for use in the EU.
Slovenian: Odbor za zdravila za uporabo v humani medicini (CHMP) pri agenciji je zaključil, da so koristi zdravila Cosentyx večje od z njim povezanih tveganj, in priporočil, da se odobri za uporabo v EU.
English: What measures are being taken to ensure the safe and effective use of Cosentyx?
Slovenian: Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Cosentyx?
English: Other information about Cosentyx
Slovenian: Druge informacije o zdravilu Cosentyx
English: Most of the side effects are mild to moderate in severity.
Slovenian: Večina neželenih učinkov je blagih do zmernih.
English: A risk management plan has been developed to ensure that Cosentyx is used as safely as possible.
Slovenian: Za zagotovitev čim varnejše uporabe zdravila Cosentyx je bil pripravljen načrt obvladovanja tveganj.
English: • moderate to severe plaque psoriasis (a disease causing red, scaly patches on the skin) when the patient needs systemic (whole body) treatment;
Slovenian: • z zmerno do hudo psoriazo v plakih (bolezni, ki povzroča rdeče, luskaste zaplate na koži), kadar bolnik potrebuje sistemsko zdravljenje (po vsem telesu);
English: The most common side effects with Cosentyx (which may affect more than 1 in 10 people) are upper respiratory tract infections (colds) with inflammation of the nose and throat (nasopharyngitis) and blocked or runny nose (rhinitis).
Slovenian: Najpogostejši neželeni učinki zdravila Cosentyx (ki lahko prizadenejo več kot 1 osebo od 10) so okužbe zgornjih dihal (prehladi) z vnetjem nosu in grla (nazofaringitisom) ter zamašenim nosom ali izcedkom iz nosu (rinitisom).
English: Cosentyx is an anti-inflammatory medicine used to treat adult patients with:
Slovenian: Zdravilo Cosentyx je protivnetno zdravilo, ki se uporablja za zdravljenje odraslih bolnikov:
English: Cosentyx can only be obtained with a prescription and treatment should only be given under the supervision of a doctor with experienced in diagnosing and treating the conditions for which Cosentyx is used.
Slovenian: Izdaja zdravila Cosentyx je le na recept, zdravljenje pa se lahko uvede le pod nadzorom zdravnika, ki ima izkušnje z diagnosticiranjem in zdravljenjem stanj, za katera se zdravilo Cosentyx uporablja.
English: This molecule is involved in the inflammation and other immune system processes that cause psoriasis and are involved in psoriatic arthritis and ankylosing spondylitis.
Slovenian: Ta molekula sodeluje pri vnetju in drugih procesih imunskega sistema, ki povzročajo psoriazo in so vključeni v psoriatični artritis in ankilozirajoči spondilitis.
English: This compares with 15% of patients on placebo.
Slovenian: Ta delež je pri bolnikih, ki so prejemali placebo, znašal 15 %.
English: By attaching to and blocking the action of interleukin 17A, secukinumab reduces the activity of the immune system and the symptoms of the disease.
Slovenian: Sekukinumab z vezavo na interlevkin 17A in zaviranjem njegovega delovanja zmanjšuje dejavnost imunskega sistema in simptome bolezni.